医学
更年期
重症监护医学
骨质疏松症
血管舒缩
激素疗法
临床试验
激素替代疗法(女性对男性)
妇科
模式
物理疗法
内科学
乳腺癌
癌症
社会科学
社会学
睾酮(贴片)
作者
Jaya Mehta,Juliana M. Kling,JoAnn E. Manson
标识
DOI:10.3389/fendo.2021.564781
摘要
Menopausal hormone therapy (HT) prescribing practices have evolved over the last few decades guided by the changing understanding of the treatment’s risks and benefits. Since the Women’s Health Initiative (WHI) trial results in 2002, including post-intervention analysis and cumulative 18-year follow up, it has become clear that the risks of HT are low for healthy women less than age 60 or within ten years from menopause. For those who are experiencing bothersome vasomotor symptoms, the benefits are likely to outweigh the risks in view of HT’s efficacy for symptom management. HT also has a role in preventing osteoporosis in appropriate candidates for treatment. A comprehensive overview of the types, routes, and formulations of currently available HT, as well as HT’s benefits and risks by outcomes of interest are provided to facilitate clinical decision making.
科研通智能强力驱动
Strongly Powered by AbleSci AI